The Next Decade of Biotech: Cross-Border Orchestrators Redefine Global Pharma Innovation
Key Insights
Asia's share of the global innovative drug pipeline has surged from 28% to 43% in five years, with China accounting for more than 85% of global pipeline growth in 2024.
Hong Kong has emerged as a critical connector hub, with its "1+" regulatory pathway enabling faster market entry and 21 new drugs approved since late 2023.
Hong Kong has raised US$17.5 billion through biotech and healthcare IPOs since 2018, ranking second globally for biotech fundraising.
The geography of biopharmaceutical innovation is undergoing a tectonic shift. For decades, the United States and Europe dominated drug discovery and development. Now, Asia is not merely catching up—it is shaping the next phase of growth. McKinsey estimates the region's share of the global innovative pipeline has risen from 28% to 43% in five years, with China accounting for nearly one-third of that volume and more than 85% of global pipeline growth in 2024. Meanwhile, the cost of drug R&D has ballooned to over US$2.6 billion.
"The next decade of biotech won't be about single-market dominance. Leadership will belong to those who can link Boston to Basel to Beijing—efficiently, safely, and at scale," industry observers note. "That connectivity is becoming the industry's defining capability."
A New Model for a Multipolar Industry
What drove biotech success in the past—capital access and top-tier lab space—is no longer sufficient. Future competitiveness will depend on the ability to integrate four key capabilities across markets: real-world data from diverse patient groups, hospital networks that can run trials at scale, regulatory strategy beyond mere compliance, and collaborative ecosystems that speed translation.
This shift is not about outsourcing; it is about co-creation. Global pharma is increasingly partnering with Chinese innovators through licensing and joint development deals, while Asian platforms draw attention in oncology, cell and gene therapies, and AI-led drug discovery. AstraZeneca's US$15 billion investment plan in China, alongside major deals involving Sanofi, Gilead, and Roche, illustrates how collaboration is redrawing biotech geography.
For industry leaders, the question is no longer whether to look East, but how to connect emerging and established biotech hubs efficiently, securely, and compliantly.
Hong Kong as the Platform for Global Health Innovation
Hong Kong is actively building an integrated platform while playing a vital connector role between Asia and the world. It combines the scale and clinical depth of the Chinese Mainland and the Greater Bay Area (GBA) with a rules-based, internationally aligned system featuring world-class R&D capabilities and strong AI-powered innovation.
Clinical data generated in Hong Kong is recognized by the FDA, EMA, and NMPA. Under the city's "1+" pathway introduced in late 2023, one reference authority certificate plus local trial data can support faster market entry, giving companies a practical route from trial to patient impact. Since launch, 21 new drugs have received approval via this process.
Global pharma has taken notice. Roche is helping shape data frameworks and policy collaboration for the GBA. AstraZeneca's Global R&D Centre in Hong Kong and iCampus for co-creation reflect confidence in the model, while Shanghai Pharmaceuticals (search) is co-investing in shared infrastructure such as 01LABS for advanced therapies.
HKSTP: Orchestrating the Ecosystem
Many of these global partnerships sit within Hong Kong Science & Technology Parks Corporation (HKSTP), the city's largest innovation and technology hub and home to more than 300 Life and Health Technology companies.
As the ecosystem orchestrator, HKSTP connects capital, talent, infrastructure, industry partners, and global market opportunities across every critical stage of the biotech innovation journey. Innovators benefit from two-way innovation acceleration through cross-border collaboration and strategic partnerships, helping global innovators access Asia's clinical depth and market scale while taking Hong Kong and Chinese Mainland biotech to the world.
HKSTP's scale-up track record includes a growing roster of home-grown and international biotech firms. Insilico Medicine (search), an AI-native unicorn with multiple AI-discovered drugs in clinical trials, completed a 2025 HKEX IPO. Arthrosi Therapeutics (search) was acquired for US$1.5 billion after a breakthrough in gout (search) treatment. Health Hope Pharma (search) secured a US$82.5 million licensing deal with Gilead Sciences for an oral anti-cancer drug.
Capital and Regulatory Advantages
In 2025, US biotech funding slowed, with only 11 drugmakers making IPOs. For biotech companies navigating the current tight domestic funding environment, Hong Kong offers an unparalleled secondary capital gateway. Since 2018, Hong Kong has raised US$17.5 billion through biotech and healthcare IPOs, ranking second globally for biotech fundraising. More than 260 biotech and healthcare companies are listed in the city, while proximity to the GBA's 88 million population offers a one-stop clinical trial platform and access to rich real-world data across therapeutic areas.
The Collaborative Imperative
Innovation in the life sciences is, by nature, collective. The complexity of today's challenges requires large groups, public authorities, universities, start-ups, and biotechs to work hand in hand. Partnership logics are increasingly accompanied by clustering, which densifies the supply and demand of technologies, ideas, and talent while fostering complementarity at global scale.
Regions such as Boston, London, the Bay Area, and Paris concentrate innovation capacity but must contend with dynamic competing hubs, particularly in Asia. China aims to transform the former city of Suzhou into a "Pharma Valley of China" by 2030, while Korea's biotech ecosystem continues to demonstrate scientific dynamism.
For innovators seeking pathways forward, the industry should focus less on choosing the "best hub" and more on connecting them. Future biotech leadership will depend on the ability to operate across data regimes, regulatory systems, and capital markets. The winners will be those that embrace collaboration not only in science, but across geography and governance.
In a world where the next breakthrough could emerge from Boston, Basel, or Beijing, the ability to move across systems quickly and credibly will help determine who brings life-changing therapies to patients first.